BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $783,894 | +102.4% | 11,516 | +142.7% | 0.09% | +36.2% |
| Q2 2023 | $387,253 | -42.2% | 4,744 | -47.5% | 0.07% | -44.8% |
| Q1 2023 | $670,010 | -27.7% | 9,031 | -19.2% | 0.12% | -43.7% |
| Q4 2022 | $926,598 | -34.2% | 11,180 | +125.6% | 0.22% | -30.6% |
| Q3 2022 | $1,408,000 | +88.5% | 4,956 | +130.0% | 0.32% | +59.2% |
| Q2 2022 | $747,000 | +112.2% | 2,155 | +216.4% | 0.20% | +66.1% |
| Q4 2021 | $352,000 | -32.8% | 681 | -37.0% | 0.12% | -29.2% |
| Q3 2021 | $524,000 | +48.9% | 1,081 | +38.4% | 0.17% | +17.9% |
| Q2 2021 | $352,000 | +20.1% | 781 | -33.9% | 0.14% | -33.5% |
| Q3 2020 | $293,000 | -47.9% | 1,181 | -53.8% | 0.22% | +26.7% |
| Q4 2019 | $562,000 | +149.8% | 2,559 | +137.4% | 0.17% | +68.6% |
| Q2 2019 | $225,000 | -24.7% | 1,078 | -42.3% | 0.10% | -65.4% |
| Q4 2018 | $299,000 | – | 1,868 | – | 0.30% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |